Huaren Pharmaceutical (300110.SZ) issued an announcement. Recently, Anhui Hengxing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (...
Zhitong Finance App News, Huaren Pharmaceutical (300110.SZ) issued an announcement. Recently, Anhui Hengxing Pharmaceutical Co., Ltd. (“Anhui Hengxing Pharmaceutical”), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for “salbutamol sulfate injection” approved and issued by the State Drug Administration. Salbutamol sulfate injection is suitable for treating respiratory diseases accompanied by bronchospasm, such as bronchial asthma or asthmatic bronchitis. It is a Class B type of national medical insurance.
This salbutamol sulfate injection has obtained a drug registration certificate and is treated as if it has passed the consistency evaluation, which will further enrich the company's respiratory product line, optimize the product structure, and have a positive impact on the company's development. Anhui Hengxing Pharmaceutical, a wholly-owned subsidiary of the company, has been deeply involved in the fields of pulmonology and narcology for many years and has accumulated a large number of core technologies. This time, it has obtained a registration certificate for salbutamol sulfate injection, which will further consolidate the company's advantages in the field of respiratory medicine and promote product development and upgrading.